AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|AAPL332.27+5.70 (+1.75%) ▲|ABBV257.12+2.12 (+0.83%) ▲|ABT101.95-1.41 (-1.36%) ▼|ACN183.90+5.99 (+3.37%) ▲|ADBE252.23+3.40 (+1.37%) ▲|AMAT456.49+2.48 (+0.55%) ▲|AMD516.13+12.53 (+2.49%) ▲|AMGN377.35-5.12 (-1.34%) ▼|AMT177.85+4.87 (+2.82%) ▲|AMZN256.78+4.89 (+1.94%) ▲|AVGO361.99+1.16 (+0.32%) ▲|AXP324.69+3.98 (+1.24%) ▲|BA210.45+5.65 (+2.76%) ▲|BAC62.69+0.13 (+0.21%) ▲|BKNG173.92+0.01 (+0.01%) ▲|BLK1,079.65+17.25 (+1.62%) ▲|BMY63.64-0.11 (-0.17%) ▼|BNY162.66+0.07 (+0.04%) ▲|BRK-B510.37+3.37 (+0.66%) ▲|C138.82+0.32 (+0.23%) ▲|CAT818.57+13.57 (+1.69%) ▲|CL86.80-1.10 (-1.25%) ▼|CMCSA25.20+0.03 (+0.12%) ▲|COF208.30+1.19 (+0.57%) ▲|COP137.35+0.31 (+0.23%) ▲|COST904.77+2.39 (+0.26%) ▲|CRM247.72+4.72 (+1.94%) ▲|CSCO112.13+4.69 (+4.37%) ▲|CVS94.66-0.63 (-0.66%) ▼|CVX214.06+1.30 (+0.61%) ▲|DE675.74-2.20 (-0.32%) ▼|DHR200.14-0.39 (-0.19%) ▼|DIS106.55+0.73 (+0.69%) ▲|DUK119.42+0.05 (+0.04%) ▲|EMR152.19+3.82 (+2.57%) ▲|FDX311.99+0.19 (+0.06%) ▲|GD355.90+1.65 (+0.47%) ▲|GE323.66-0.49 (-0.15%) ▼|GEV957.27+33.36 (+3.61%) ▲|GILD143.72-1.09 (-0.75%) ▼|GM85.62-0.50 (-0.58%) ▼|GOOG335.45+5.06 (+1.53%) ▲|GOOGL338.50+5.90 (+1.77%) ▲|GS1,029.18+9.41 (+0.92%) ▲|HD308.74+3.05 (+1.00%) ▲|HON202.36+0.18 (+0.09%) ▲|IBM243.29+9.27 (+3.96%) ▲|INTC102.94+2.62 (+2.61%) ▲|INTU321.57+8.80 (+2.81%) ▲|ISRG369.15+8.69 (+2.41%) ▲|JNJ265.58-0.77 (-0.29%) ▼|JPM356.23+2.67 (+0.76%) ▲|KO88.29+0.46 (+0.52%) ▲|LIN466.22+4.60 (+1.00%) ▲|LLY1,115.70-7.30 (-0.65%) ▼|LMT524.19-5.93 (-1.12%) ▼|LOW196.82+0.23 (+0.12%) ▲|LRCX298.22+0.21 (+0.07%) ▲|MA569.19+3.82 (+0.68%) ▲|MCD252.53-0.52 (-0.21%) ▼|MDLZ62.44-0.03 (-0.05%) ▼|MDT90.96-0.66 (-0.72%) ▼|META648.03+3.65 (+0.57%) ▲|MMM164.97+2.11 (+1.30%) ▲|MO68.98+0.19 (+0.28%) ▲|MRK143.93-0.78 (-0.54%) ▼|MS214.38+1.72 (+0.81%) ▲|MSFT495.63+3.19 (+0.65%) ▲|MU975.26-2.15 (-0.22%) ▼|NEE82.31-0.13 (-0.16%) ▼|NFLX77.40+1.39 (+1.83%) ▲|NKE36.80+0.18 (+0.49%) ▲|NOW132.53+1.36 (+1.04%) ▲|NVDA218.29-0.07 (-0.03%) ▼|ORCL150.28-2.66 (-1.74%) ▼|PEP136.32-0.33 (-0.24%) ▼|PFE27.72+0.07 (+0.25%) ▲|PG145.27+2.30 (+1.61%) ▲|PLTR167.23+1.37 (+0.83%) ▲|PM191.06+1.29 (+0.68%) ▲|QCOM181.97+5.09 (+2.88%) ▲|RTX197.68-0.44 (-0.22%) ▼|SBUX98.74-0.48 (-0.48%) ▼|SCHW107.25-0.08 (-0.07%) ▼|SO87.17-0.58 (-0.66%) ▼|SPG204.83+0.16 (+0.08%) ▲|T26.06+0.51 (+2.00%) ▲|TMO609.82+6.64 (+1.10%) ▲|TMUS182.33+5.17 (+2.92%) ▲|TSLA365.44+1.88 (+0.52%) ▲|TXN268.70+9.88 (+3.82%) ▲|UBER71.67-0.89 (-1.23%) ▼|UNH379.09-9.19 (-2.37%) ▼|UNP284.40-1.38 (-0.48%) ▼|UPS100.28+0.31 (+0.31%) ▲|USB62.84+0.43 (+0.69%) ▲|V370.45+3.24 (+0.88%) ▲|VZ50.61+0.64 (+1.28%) ▲|WFC90.29+0.84 (+0.94%) ▲|WMT107.15+1.42 (+1.34%) ▲|XOM165.99+0.76 (+0.46%) ▲|
22.7 C
New York
Sunday, September 13, 2026

Tag: future

newssourceFORcompanyinformationcontent1releasesmarket

Salomon Unfolds the Next Chapter of ROAD TO THE FUTURE in Shanghai

SHANGHAI, June 14, 2026 (GLOBE NEWSWIRE) -- French outdoor brand Salomon has officially unsealed the latest instalment of the ROAD TO THE FUTURE programme at the Anfu concept store in Shanghai, China. This event unveiled the full launch of the 2026 Road to the Future Design Competition. Guest designer Uma Wang joins eight emerging designers to debut exclusive collaborative footwear designs, coinciding with the public opening of the project’s in-store display and official launch of public voting phase. Salomon China brand ambassador Bai Jingting attended the opening event, uniting established designers, cross-industry professionals and industry medias to dissect the evolving trajectory of the emerging boundaries of outdoor and fashion industry. In the future, Salomon will continuously explore the boundaries of outdoor aesthetics through creativities.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of GRAIL, Inc. (NASDAQ: GRAL) between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 4, 2026.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Roblox Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – RBLX

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Roblox Corporation (NYSE: RBLX) between October 30, 2025 and April 30, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2026.

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VERI

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Veritone, Inc. (NASDAQ: VERI) between October 14, 2025 and April 14, 2026, inclusive (the “Class Period”), of the important July 20, 2026 lead plaintiff deadline.

PHREESIA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Phreesia, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PHR

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Phreesia, Inc. (NYSE: PHR) between May 8, 2025 and March 30, 2026, inclusive (the “Class Period”), of the important July 13, 2026 lead plaintiff deadline.

BABCOCK & WILCOX DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Babcock & Wilcox Enterprises, Inc. Investors to Secure Counsel Before Important June 15 Deadline in...

NEW YORK, June 13, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Babcock & Wilcox Enterprises, Inc. (“B&W”) (NYSE: BW) between November 5, 2025 and March 11, 2026, inclusive (the “Class Period”), of the important June 15, 2026 lead plaintiff deadline.

Nalvurikenz Officially Launches Its Advanced AI Trading Platform for the Next Generation of Intelligent Investing in 2026

New York City, June 13, 2026 (GLOBE NEWSWIRE) --

In 2026, Nalvurikenz officially announced the release of its new AI-powered trading platform, integrating unique features and functionalities to simplify the trading process using a combination of artificial intelligence, live data analytics, and advanced automation.

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – CNS, kidney, small intestine, and bone – as demonstrated by improved quality of life and normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density. These benefits were sustained while enabling independence from conventional therapy with active vitamin D and calcium.

Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Media Release

COPENHAGEN, Denmark; June 13, 2026

TTW Announces Top 50 Amusement Park Travel Destinations in the World for 2026

NEW YORK, June 13, 2026 /PRNewswire/ -- Travel And Tour World (TTW) today announced its Top 50 Amusement Park Travel Destinations in the World...

MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations

GOTHENBURG, Sweden, June 13, 2026 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation...

NASDAQ: WGS: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against GeneDx Holdings Corp. (WGS)

Did you buy WGS securities between April 16, 2025, and May 4, 2026?

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFuture

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers